Description

1. Product Overview: Elopag 50® is an oral thrombopoietin receptor agonist containing Eltrombopag, used to increase platelet counts in patients with chronic immune thrombocytopenia and other thrombocytopenic conditions.

2. Composition: Eltrombopag INN 50 mg | Dosage Form: Tablet

3. Pharmacological Class: Thrombopoietin (TPO) Receptor Agonist

4. Mechanism of Action: Eltrombopag stimulates thrombopoietin receptors on megakaryocyte precursors in the bone marrow, increasing platelet production and reducing bleeding risk.

5. Indications: Chronic immune thrombocytopenia (ITP) | Thrombocytopenia associated with chronic liver disease | Other thrombocytopenic conditions as prescribed

6. Dosage & Administration: As directed by physician or hematology specialist only | Oral use | Usually taken once daily | Should be taken on an empty stomach or as advised

7. Clinical Benefits: Increases platelet count | Reduces bleeding risk | Helps avoid platelet transfusions in selected cases | Supports safe medical procedures

8. Contraindications: Hypersensitivity to Eltrombopag or any component of the formulation

9. Precautions: Risk of hepatotoxicity and liver enzyme elevation | Regular liver function and platelet monitoring required | Risk of thrombosis if platelet count becomes high

10. Drug Interactions: May interact with polyvalent cations (calcium, magnesium, aluminum, iron) which reduce absorption

11. Special Populations: Use in pregnancy and lactation only if clearly necessary and prescribed | Pediatric use under specialist supervision

12. Adverse Effects: Nausea | Headache | Fatigue | Elevated liver enzymes | Increased risk of thrombosis (rare)

13. Storage Conditions: Store below 30°C | Protect from light and moisture | Keep out of reach of children

14. Packaging: Tablet blister pack

15. Manufacturer: Everest Pharmaceutical Ltd.